Drug Trial Radar · NCT02993406
Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo
Last checked: Nov 20, 2026Latest source record: Jan 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
13,970
Actual
Start
Dec 22, 2016
Primary completion
Nov 7, 2022
Study completion Nov 7, 2022
Sponsor
- Lead sponsor
- Esperion Therapeutics, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- The Cleveland Clinic
- First posted
- Dec 15, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine if treatment with bempedoic acid (ETC-1002) versus placebo decreases the risk of cardiovascular events in participants who have or are at high risk for cardiovascular disease and are statin intolerant.
Conditions
- Cardiovascular Diseases
- Statin Adverse Reaction
Interventions
Bempedoic acid 180 mg tabletDrug
Patients take bempedoic acid 180 mg tablet orally once daily
Matching placebo tabletDrug
Patients take matching placebo tablet orally once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With First Occurrence of Four Component Major Adverse Cardiovascular Events (MACE)Time frame: Up to 68 months
Locations
1,319 sites in 32 countries. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Birmingham, Alabama
Site not named
Huntsville, Alabama
Site not named
Mobile, Alabama
Site not named
Mobile, Alabama
Site not named
Pell City, Alabama
Site not named
Tuscumbia, Alabama
Site not named
Chandler, Arizona
Site not named
Cottonwood, Arizona
Site not named
Fountain Hills, Arizona
Site not named
Gilbert, Arizona
Site not named
Glendale, Arizona
Site not named
Glendale, Arizona
Site not named
Mesa, Arizona
Site not named
Phoenix, Arizona
Site not named
Phoenix, Arizona
Site not named
Tucson, Arizona
Site not named
Tucson, Arizona
Site not named
Beverly Hills, California
Site not named
Carlsbad, California
Site not named
Huntington Beach, California
Site not named
Lincoln, California
Site not named
Long Beach, California
Site not named
Long Beach, California
Site not named
Northridge, California
Site not named
Oceanside, California
Site not named
Rancho Cucamonga, California
Site not named
San Diego, California
Site not named
Santa Ana, California
Site not named
Santa Rosa, California
Site not named
Torrance, California
Site not named
Vista, California
Site not named
Aurora, Colorado
Site not named
Colorado Springs, Colorado
Site not named
Colorado Springs, Colorado
Site not named
Golden, Colorado
Site not named
Littleton, Colorado
Site not named
Loveland, Colorado
Site not named
Hamden, Connecticut
Site not named
Hartford, Connecticut
Showing 40 of 1,319 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.